Entrada: Moving cell-penetrating DMD therapy into clinic with $116M series B

With $116 million to deploy from its new series B crossover round, Entrada has concluded that DMD is its top priority among many potential applications of its platform for delivering biologics to intracellular targets.

Founded in 2016 and incubated in 5AM Ventures’ 4:59 program, Entrada Therapeutics Inc. has a core technology that uses peptide conjugates to deliver biologic payloads into cells...